8-K filing — Acrivon Therapeutics, Inc. (ACRV)
Filed: 2026-08-12 AccNo: 0001193125-26-346859 Size: 435 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Acrivon Therapeutics Q2 EPS $(0.43) Beats $(0.50) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 21.82 percent increase over losses of $(0.55) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 12, 2026, 8:23 PM
- Checked
- Aug 12, 2026, 8:23 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Acrivon Therapeutics Says ACR-2316 Advances Into Randomized Dose Expansion Portion Of Its Ongoing Phase 1/2 Study
Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a yearOral weekly regimen (3 days on/4 days
Read original at benzingaAcrivon Therapeutics To Highlight AP3 Platform For Pathway-Based Drug Discovery And Development At AACR D3 July 21-24
Presentations and DetailsOral Podium PresentationTitle: Acrivon Predictive Precision Proteomics (AP3): Next Generation Precision Medicine for Phosphoproteomics-Guided Drug DiscoveryPresenter: Lei Shi, Ph.D., Director
Read original at benzinga